Boehringer Ingelheim launches AI centre for pharma research in London

Bengaluru: German drugmaker Boehringer Ingelheim is launching a ​centre for artificial ​intelligence and machine learning in London, it said ​on Monday, as it seeks to expand its AI capabilities in pharmaceutical research and development.

Drugmakers are increasingly turning to AI ‌to reduce ⁠the ⁠most time-consuming aspects of drug development, from trial recruitment and site ​selection to regulatory paperwork, even as industry leaders acknowledge the technology ​has fallen short in discovering major new molecules.

London to be company’s fourth location after Austria, Germany, ​and U.S. specialized in using ⁠advanced computing methods, ‌such as algorithms, data analysis, ​and AI ​to improve processes and accelerate discovery

Focus ⁠on developing targeted medicines for patients with unmet ​medical needs

Boehringer to invest 150 million ​pounds ($200 million) over 10 years

“The UK has a strong legacy in AI, and the government’s continued commitment to advancing data-driven innovation in life sciences and healthcare makes it an ideal location,” said Paola Casarosa, ‌Global Head, Innovation Unit at Boehringer Ingelheim

Centre located near King’s Cross ​station in ​Knowledge Quarter area of ⁠London, which hosts many AI companies including OpenAI, Google and Meta

Britain has recently pushed to cast itself ​as an “AI superpower” and a home for cutting-edge research

Swiss drugmaker Roche said has expanded its AI computing capacity with more than 2,100 Nvidia chips

Related Posts

Annovis Bio receives US patent covering new crystalline form of buntanetap

Annovis Bio, Inc. (Annovis), a phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), announced that…

Bengaluru: Medical devices worth ₹13.79 lakh seized in enforcement drive

The enforcement wing of Karnataka’s Food Safety and Drugs Control Department has seized medical devices and consumables worth ₹13.79 lakh from two establishments in Bengaluru’s Cottonpet area for alleged violations…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Annovis Bio receives US patent covering new crystalline form of buntanetap

Annovis Bio receives US patent covering new crystalline form of buntanetap

Bengaluru: Medical devices worth ₹13.79 lakh seized in enforcement drive

Bengaluru: Medical devices worth ₹13.79 lakh seized in enforcement drive

Yashoda Medicity Unveils T-Shirts & Finisher Medals ahead of Yashoda Half Marathon 4.0

Yashoda Medicity Unveils T-Shirts & Finisher Medals ahead of Yashoda Half Marathon 4.0

PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels

From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels